Comparison in Patients < 75 Years of Age - Versus - Those > 75 Years on One-year-Events With Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German LAARGE Registry).


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 29 06 2020
revised: 28 08 2020
accepted: 01 09 2020
pubmed: 19 9 2020
medline: 1 1 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation therapy in patients with non-valvular atrial fibrillation for the prevention of embolic stroke and systemic embolism. Although elderly patients (>75 years) have both higher ischemic and bleeding risk as compared with younger patients, they benefit from optimal anticoagulation. The subanalysis aimed to assess the indications, the safety, efficacy, and 1-year outcomes of interventional LAAC in elderly patients (≥ 75 years) compared with younger (< 75 years) patients in clinical practice. We analyzed data from the prospective Left-Atrium-Appendage Occluder Registry Germany. A total of 638 patients were included in the registry, 402 (63%) were aged ≥ 75 years. Compared with younger subjects, patients aged ≥75 were more likely to have higher CHA2DS2-VASC and HAS-BLED scores. Procedural success rate was high und similar in both groups (97.6%). Periprocedural adverse events were not statistically significant in groups (11.9% in <75 years vs 12.9% in ≥75 years; p = 0.80). At 1 year follow-up, all-cause mortality was higher in patients aged ≥75 compared withwith younger group (13.0% vs 7.8 %,p = 0.04), mainly due to non-cardiovascular causes (10.6% vs 6.0%). No significant differences in major bleeding, stroke, systemic embolism were observed. In conclusion, LAAC is feasible and safe in patients with AF at high stroke risk and with contraindications for OAC and should be considered as candidates for LAA closure. Elderly patients often present these characteristics and could benefit from this novel therapy.

Identifiants

pubmed: 32946860
pii: S0002-9149(20)30955-3
doi: 10.1016/j.amjcard.2020.09.017
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

81-86

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relations that could have appeared to influence the work reported in this study.

Auteurs

Aref El Nasasra (AE)

Klinikum Ludwigshafen, Ludwigshafen, Germany.

Johannes Brachmann (J)

Department of Cardiology, Angiology, and Pneumology, Second Medical Clinic, Coburg Hospital, Coburg, Germany.

Thorsten Lewalter (T)

Department of Medicine-Cardiology and Intensive Care, Hospital Munich-Thalkirchen, Munich, Germany; First Department of Medicine,University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany.

Ibrahim Akin (I)

First Department of Medicine,University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany.

Horst Sievert (H)

CardioVascular Center Frankfurt, Frankfurt, Germany and Anglia Ruskin University, Chelmsford, United Kingdom.

Christoph A Nienaber (CA)

Cardiology and Aortic Center, Royal Brompton and Harefield NHS Foundation, Trust at Imperial College, London, United Kingdom.

Christian Weiß (C)

Department of Cardiology, Klinikum Lüneburg, Lüneburg, Germany.

Sven T Pleger (ST)

Department of Internal Medicine III, Division of Cardiology, University of Heidelberg, Heidelberg, Germany.

Hüseyin Ince (H)

Clinic for Internal Medicine, University of Rostock, Rostock, Germany and Vivantesklinikum im Friedrichshain und Am Urban, Berlin, Germany.

Jens Maier (J)

Medical Department I, SLK-Kliniken Heilbronn GmbH, Klinikum Am Gesundbrunnen, Heilbronn, Germany.

Stephan Achenbach (S)

Department of Medicine, University of Erlangen, Erlangen, Germany.

Holger H Sigusch (HH)

Clinic for Internal Medicine I, Heinrich-Braun-Klinikum Zwickau gGmbH, Zwickau, Deutschland.

Matthias Hochadel (M)

Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.

Steffen Schneider (S)

Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.

Jochen Senges (J)

Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.

Uwe Zeymer (U)

Klinikum Ludwigshafen, Ludwigshafen, Germany; Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.. Electronic address: Uwe.Zeymer@t-online.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH